The FDA warns that the Raindrop Near Vision Inlay is linked to corneal haze and vision problems. The agency reports a 75% rate of corneal haze after five years and says it is working with the manufacturer to remove the product from the market.
ReVision Optics’ shutdown follows challenges that thwart its effort to establish a place in the market for corneal inlays that treat presbyopia. The article describes sales of these inlays as a business that could prove lucrative for a company in the future.
Feb 2018 · Ophthalmology Innovation SourceNews article
ReVision Optics, maker of the Raindrop near vision inlay, announces that it has closed its doors. The company says the inlay will no longer be sold to ophthalmic practices or distributors as of Tuesday, January 30, 2018, according to a notice on its website.
ReVision Optics raises $32 million in an equity round to support commercialization of its Raindrop near-vision inlay. Existing investors Canaan Partners, Domain Associates, InterWest Partners, and ProQuest Investments also participated; the inlay received FDA pre-market approval in June.
